Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes

Documenti analoghi

• BCPT 2026 Policy for Experimental and Clinical Studies
  di: Pernille Tveden‐Nyborg, et al.
  Pubblicazione: (2025)
• Mechanisms of resistance to daratumumab in patients with multiple myeloma
  di: Katrine Fladeland Iversen
  Pubblicazione: (2024)
• Medication use among the oldest old in the Faroe Islands—A national cross‐sectional study
  di: Beinta Joensen, et al.
  Pubblicazione: (2024)
• Blood Pressure–Lowering Effects of Aldosterone Synthase Inhibitors—A Systematic Review
  di: Anders Almskou Rasmussen, et al.
  Pubblicazione: (2025)
• Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care
  di: Sarwat Amna, et al.
  Pubblicazione: (2024)